Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
As dermo-cosmetics inventors, Pierre Fabre Dermo Cosmetics innovates in skin care and hair care fields and solutions following a sacrosanct principle of beauty rooted in ethics.
Backed by a pharmaceutical laboratory, the key to our scientific excellence, Pierre Fabre designs dermo-cosmetic treatments according to the most rigorous criteria for efficacy and safety. At Pierre Farbe, we are focused on acquiring the most cutting-edge expertise and technology, particularly in natural substances, hydrotherapy in dermatology, biotechnologies, and sterile cosmetics.
Recommended by health care professionals, our dermo-cosmetic treatments are administered by staff trained in our beauty ethics approach, thus guaranteeing individually tailored solutions.
As specialists in dermatological therapy with Pierre Fabre Dermatology we are no. 1 in Europe and no. 2 globally on the dermo-cosmetics market, with sales of over €1 billion across 130 countries, and a portfolio of 10 complementary brands.
Pierre Fabre is committed to developing our brands in all parts of the world. Each brand in our portfolio has its own DNA and is positioned to target a different type skin types and needs. Our brands are based on natural active ingredients: thermal spring water for Avène, Rhealba® Oat for A-Derma, plant extracts for Klorane and Elancyl, essential oils and plant extracts for René Furterer. Our dermo-cosmetics products are developed, clinically tested and manufactured according to the standards set out by the pharmaceutical industry.
Contact
Pierre Fabre Dermo-Cosmetics
Les Cauquillous
81506 Lavaur Cedex
+33 149 10 81 68
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
See our Cookie Privacy Policy Here
